Abstract
Background Schizophrenia spectrum disorders and schizotypy share traits across positive, negative, and disorganized domains. Instruments like MSS and O-LIFE provide insights into these dimensions. Despite challenges posed by cultural variations and measurement methodologies, these instruments offer nuanced perspectives on the spectrum of schizotypy, spanning from its expression as a personality trait to its potential implications in clinical settings.
Methods Through an Exploratory Graph Analysis (EGA) applied to a sample of 1059 healthy subjects, we compare the resulting networks with the original factorial structure of the two questionnaires and explore how each one conceptualizes schizotypy. Comparing both models quantitatively and qualitatively these models, we seek to elucidate the unique insights provided by each instrument regarding the spectrum of schizotypy as a personality trait.
Results EGA analyses unveiled a three-dimensional structure plus an additional one consisting of items related to the concept of “Disconnection”. Confirmatory factor analysis showed this four-dimensional model outperformed others. High reliability and strong factor saturation were observed for all four factors.
O-LIFE’s EGA revealed a complex structure, refined to four factors removing items with low fitting indices from the scale. Confirmatory analysis validated a final model with robust reliability and well-defined factor structures across the new “Cognitive and Behavioural Disorganization”, “Introversion”, “Unusual Experiences”, and “Environmental Pressure” factors.
Conclusions This study improves the understanding of schizotypy by proposing new MSS and O-LIFE factor structures via EGA. Both scales uniquely contribute to schizotypy assessment in healthy populations, warranting further research to validate and refine these new domains across diverse populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Brain & Behavior Research Foundation (Grant No. 28997) and the OPO Research Foundation (Grant No. 2020-0075) to Werner Surbeck.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The authors assert that the protocol was approved by the Kantonale Ethikkimmission of Zurich (KEK-ZH 2020/01049) and that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding Authors
